Four Cases of Interstitial Lung Disease Induced by Erlotinib 
and A Review of the Literatures

Four Cases of Interstitial Lung Disease Induced by Erlotinib 
and A Review of the Literatures

Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors which are used for non-small cell lung cancer. Although this class of agents is considered to be relatively safe, the most serious, but rare, adverse reaction is drug-associated interstitial lung disease...

Full description

Bibliographic Details
Main Authors: Xiaoling WU, Guanghui GAO, Shengxiang REN, Caicun ZHOU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2012-08-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Erlotinib
Epidermal growth factor receptor
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2012.08.08

Similar Items

Similar Items